Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia

Infection and Immunity

Volumn 81, Issue 3, 2013, Pages 984-995

  Linke, Michael J ^a,b   Ashbaugh, Alan ^a,b   Collins, Margaret S ^a,b   Lynch, Keeley ^a,b   Cushiona, Melanie T ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; BETA 1,3 GLUCAN; BETA GLUCAN; MACROPHAGE INFLAMMATORY PROTEIN;

ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; INFLAMMATION; LIFE CYCLE; LUNG; LUNG CLEARANCE; LUNG INJURY; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PNEUMOCYSTIS; PNEUMOCYSTIS MURINA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL;

ALBUMINS; ANIMALS; ANTIFUNGAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CELL WALL; ECHINOCANDINS; FEMALE; FLOW CYTOMETRY; INFLAMMATION; LUNG; MICE; MICE, INBRED C3H; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS;

EID: 84874740952     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01181-12     Document Type: Article

References (62)

1. Levitz SM. 2010. Innate recognition of fungal cell walls. PLoS Pathog. 6:e1000758. doi:10.1371/journal.ppat.1000758.
2. Liu J, Balasubramanian MK. 2001. 1,3-Beta glucan synthase: a useful target for antifungal drugs. Curr. Drug Targets Infect. Disord. 1:159-169.
3. Beck JM, Cushion MT. 2009. Pneumocystis workshop: 10th anniversary summary. Eukarot. Cell 8:446-460.
4. Williams DJ, Radding JA, Dell A, Khoo KH, Rogers ME, Richards FF, Armstrong MY. 1991. Glucan synthesis in Pneumocystis carinii. J. Protozool. 38:427-437.
5. Kottom TJ, Limper AH. 1999. Assembly of cell wall glucans by Pneumocystis carinii: characterization of the Gsc-1 subunit mediating beta-glucan synthesis. J. Eukaryot. Microbiol. 46(Suppl):131S.
6. Kottom TJ, Limper AH. 2000. Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta-1,3-glucan deposition. J. Biol. Chem. 275:40628-40634.
7. Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD. 2010. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 5:e8524. doi:10.1371/journal.pone.0008524.
8. Carmona EM, Lamont JD, Xue A, Wylam M, Limper AH. 2010. Pneumocystis cell wall beta-glucan stimulates calcium-dependent signaling of IL-8 secretion by human airway epithelial cells. Respir. Res. 11:95. doi:10.1186/1465-9921-11-95.
9. Carmona EM, Vassallo R, Vuk-Pavlovic Z, Standing JE, Kottom TJ, Limper AH. 2006. Pneumocystis cell wall beta-glucans induce dendritic cell costimulatory molecule expression and inflammatory activation through a Fas-Fas ligand mechanism. J. Immunol. 177:459-467.
10. Evans SE, Hahn PY, McCann F, Kottom TJ, Pavlovic' ZV, Limper AH. 2005. Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaB-dependent mechanisms. Am. J. Respir. Cell Mol. Biol. 32:490-497.
11. Hahn PY, Evans SE, Kottom TJ, Standing JE, Pagano RE, Limper AH. 2003. Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide- mediated mechanism. J. Biol. Chem. 278:2043-2050.
12. Hahn PY, Limper AH. 2001. Pneumocystis carinii beta-glucan induces release of macrophage inflammatory protein-2 from primary rat alveolar epithelial cells via a receptor distinct from CD11b/CD18. J. Eukaryot. Microbiol. 48(Suppl):157S.
13. Vassallo R, Standing J, Limper AH. 1999. Beta-glucan from Pneumocystis carinii stimulates TNF alpha release from alveolar macrophages. J. Eukaryot. Microbiol. 46(Suppl):145S.
14. Carmona EM, Kottom TJ, Hebrink DM, Moua T, Singh RD, Pagano RE, Limper AH. 2012. Glycosphingolipids mediate pneumocystis cell wall beta-glucan activation of the IL-23/IL-17 axis in human dendritic cells. Am. J. Respir. Cell Mol. Biol. 47:50-59.
15. Castro M, Morgenthaler TI, Hoffman OA, Standing JE, Rohrbach MS, Limper AH. 1993. Pneumocystis carinii induces the release of arachidonic acid and its metabolites from alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 9:73-81.
16. Hoffman OA, Standing JE, Limper AH. 1993. Pneumocystis carinii stimulates tumor necrosis factor-alpha release from alveolar macrophages through a beta-glucan-mediated mechanism. J. Immunol. 150:3932-3940.
17. Limper AH, Lebron F, Evans SE, Hahn RY. 2003. Pneumocystis carinii: cell wall beta-glucan-mediated pulmonary inflammation. J. Eukaryot. Microbiol. 50(Suppl):646.
18. Vassallo R, Standing JE, Limper AH. 2000. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J. Immunol. 164:3755-3763.
19. Costa JM, Botterel F, Cabaret O, Foulet F, Cordonnier C, Bretagne S. 2012. Association between circulating DNA, serum (1→3)-beta-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia. Clin. Infect. Dis. 55:e5-e8.
20. Matsumura Y, Ito Y, Iinuma Y, Yasuma K, Yamamoto M, Matsushima A, Nagao M, Takakura S, Ichiyama S. 2012. Quantitative real-time PCR and the (1→3)-beta-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin. Microbiol. Infect. 18: 591-597.
21. Sax PE, Komarow L, Finkelman MA, Grant PM, Andersen J, Scully E, Powderly WG, Zolopa AR. 2011. Blood (1→3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin. Infect. Dis. 53:197-202.
22. Damiani C, Le Gal S, Lejeune D, Brahimi N, Virmaux M, Nevez G, Totet A. 2011. Serum (1→3)-beta-D-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J. Clin. Microbiol. 49:2000-2002.
23. Cuetara MS, Alhambra A, Chaves F, Moragues MD, Ponton J, Del Palacio A. 2008. Use of a serum (1→3)-beta-D-glucan assay for diagnosis and follow-up of Pneumocystis jirovecii pneumonia. Clin. Infect. Dis. 47:1364-1366.
24. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, Ishizaka A. 2007. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 131:1173-1180.
25. Kawayama T, Fujiki R, Honda J, Rikimaru T, Aizawa H. 2003. High concentration of (1→3)-beta-D-glucan in BAL fluid in patients with acute eosinophilic pneumonia. Chest 123:1302-1307.
26. Schmatz DM, Powles MA, McFadden D, Nollstadt K, Bouffard FA, Dropinski JF, Liberator P, Andersen J. 1995. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob. Agents Chemother. 39:1320-1323.
27. Matsumoto Y, Yamada M, Amagai T. 1991. Yeast glucan of Pneumocystis carinii cyst wall: an excellent target for chemotherapy. J. Protozool. 38:6S-7S.
28. Schmatz DM, Powles M, McFadden DC, Pittarelli LA, Liberator PA, Anderson JW. 1991. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3- beta-glucan synthesis inhibitor L-671,329. J. Protozool. 38:151S-153S.
29. Vanmiddlesworth F, Omstead MN, Schmatz D, Bartizal K, Fromtling R, Bills G, Nollstadt K, Honeycutt S, Zweerink M, Garrity G.1991. L-687,781, a new member of the papulacandin family of beta-1,3-Dglucan synthesis inhibitors. I. Fermentation, isolation, and biological activity. J. Antibiot. (Tokyo) 44:45-51.
30. Schmatz DM, Romancheck MA, Pittarelli LA, Schwartz RE, Fromtling RA, Nollstadt KH, Vanmiddlesworth FL, Wilson KE, Turner MJ. 1990. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc. Natl. Acad. Sci. U. S. A. 87:5950-5954.
31. Mukherjee PK, Sheehan D, Puzniak L, Schlamm H, Ghannoum MA. 2011. Echinocandins: are they all the same? J. Chemother. 23:319-325.
32. Patel N, Koziel H. 2004. Pneumocystis jirovecii pneumonia in adult patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy. Treat. Respir. Med. 3:381-397.
33. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC.
34. Animal and Plant Health Inspection Service. Animal Welfare Act Regulations. Animal and Plant Health Inspection Service, US Department of Agriculture, Washington, DC. http://www.aphis.usda.gov/animal_welfare/index.shtml.
35. National Institutes of Health. 2000. Public Health Service policy on humane care and use of laboratory animals. Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD.
36. Cushion MT, Walzer PD. 2009. Preclinical drug discovery for new antipneumocystis compounds. Curr. Med. Chem. 16:2514-2530.
37. Linke M, Ashbaugh A, Koch J, Tanaka R, Walzer P. 2006. Efficient resolution of Pneumocystis murina infection in surfactant protein A-deficient mice following withdrawal of corticosteroid-induced immunosuppression. J. Med. Microbiol. 55:143-147.
38. McFadden DC, Powles MA, Pittarelli LA, and Schmatz DM. 1991. Establishment of Pneumocystis carinii in various mouse strains using natural transmission to initiate infection. J. Protozool. 38:126S-127S.
39. Russell WMS, Burch RL. 2012. The principles of humane experimental technique. CAAT, Johns Hopkins University, Baltimore, MD.
40. Cushion MT, Collins MS, Linke MJ. 2009. Biofilm formation by Pneumocystis spp. Eukaryot. Cell 8:197-206.
41. Linke M, Ashbaugh A, Koch J, Tanaka R, Walzer P. 2005. Surfactant protein A limits Pneumocystis murina infection in immunosuppressed C3H/HeN mice and modulates host response during infection. Microbes Infect. 7:748-759.
42. Steele C, Marrero L, Swain S, Harmsen AG, Zheng M, Brown GD, Gordon S, Shellito JE, Kolls JK. 2003. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J. Exp. Med. 198:1677-1688.
43. Collins MS, Cushion MT. 2001. Standardization of an in vitro drug screening assay by use of cryopreserved and characterized Pneumocystis carinii populations. J. Eukaryot. Microbiol. 48(Suppl):178S-179S.
44. Swain SD, Meissner NN, Siemsen DW, McInnerney K, Harmsen AG. 2012. Pneumocystis elicits a STAT6-dependent, strain specific innate immune response and airway hyperresponsiveness. Am.J. Respir. Cell Mol. Biol. 46:290-298.
45. Hohl TM, Feldmesser M, Perlin DS, Pamer EG. 2008. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J. Infect. Dis. 198: 176-185.
46. Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, Raad II, Kontoyiannis DP. 2008. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198:186-192.
47. Dunyach C, Drakulovski P, Bertout S, Jouvert S, Reynes J, Mallie M. 2011. Fungicidal activity and morphological alterations of Candida albicans induced by echinocandins: study of strains with reduced caspofungin susceptibility. Mycoses 54:e62-e68. doi:10.1111/j.1439-0507.2009.01834.x.
48. Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, Danielson ME, Weiss A, Vasilakos JP, Underhill DM. 2011. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse.' Nature 472:471-475.
49. Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J. 2011. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood 117:6825-6836.
50. Shellito JE, Tate C, Ruan S, Kolls J. 2000. Murine CD4+ T lymphocyte subsets and host defense against Pneumocystis carinii. J. Infect. Dis. 181: 2011-2017.
51. Beck JM, Newbury RL, Palmer BE, Warnock ML, Byrd PK, Kaltreider HB. 1996. Role of CD8+ lymphocytes in host defense against Pneumocystis carinii in mice. J. Lab. Clin. Med. 128:477-487.
52. Gigliotti F, Crow EL, Bhagwat SP, Wright TW. 2006. Sensitized CD8+ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia. Infect. Immun. 74:6310-6316.
53. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. 1997. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect. Immun. 65:5052-5056.
54. McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK. 2006. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J. Immunol. 177:6215-6226.
55. Evans SE, Kottom TJ, Pagano RE, Limper AH. 2012. Primary alveolar epithelial cell surface membrane microdomain function is required for Pneumocystis beta-glucan-induced inflammatory responses. Innate Immun. 18:709-716.
56. Konrad FM, Reutershan J. 6 June 2012. CXCR2 in acute lung injury. Mediators Inflamm. 2012. doi:10.1155/2012/740987.
57. Zhang C, Lei GS, Shao S, Jung HW, Durant PJ, Lee CH. 2012. Accumulation of myeloid-derived suppressor cells in the lungs during Pneumocystis pneumonia. Infect. Immun. 80:3634-3541.
58. Koval CE, Gigliotti F, Nevins D, Demeter LM. 2002. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin. Infect. Dis. 35:491-493.
59. Wislez M, Bergot E, Antoine M, Parrot A, Carette MF, Mayaud C, Cadranel J. 2001. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am. J. Respir. Crit. Care Med. 164:847-851.
60. Briel M, Boscacci R, Furrer H, Bucher HC. 2005. Adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect. Dis. 5:101. doi:10.1186/1471-2334-5-101.
61. Singh N, Perfect JR. 2007. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect. Dis. 7:395-401.
62. Perfect JR. 2012. The impact of the host on fungal infections. Am. J. Med. 125:S39-S51.